NIH MIRA R35 Grant Explained: 3 Eligibility Routes

The NIH MIRA (R35), the Maximizing Investigators’ Research Award, is a single National Institute of General Medical Sciences grant that funds an investigator’s entire mission-relevant research programme rather than one discrete project. It replaces multiple project-based awards — typically R01s — with one five-year, higher-flexibility grant, and eligibility runs through three distinct routes: Early Stage Investigator (ESI), New Investigator (NI), and Established Investigator (EI).

The NIH MIRA R35 is best understood as a programme-level funding mechanism: NIGMS states it provides “a single NIGMS grant per PI to provide support for NIGMS-related research in an investigator’s lab,” with increased award length, funding stability, and reduced administrative burden compared with managing several R01s.

• What is the NIH MIRA (R35) grant?
• Which eligibility route applies — ESI, New Investigator, or Established Investigator?
• How does MIRA governance differ from renewing an R01?
• How does a MIRA interact with a P01 or other multi-project award?
• Common questions about the NIH MIRA R35
• What this means for research administrators

What is the NIH MIRA (R35) grant?

The Maximizing Investigators’ Research Award is NIGMS’s implementation of the NIH-wide R35 activity code. Where most R35 mechanisms across NIH institutes are branded differently, NIGMS’s version consolidates an investigator’s mission-relevant projects into one award and drops the specific-aims framework used in R01 review.

NIGMS’s FAQ on the Established/New Investigator MIRA (PAR-22-180, superseded by PAR-26-121) names three defining features: it funds a broad research programme rather than a narrowly scoped project; it gives flexibility to pursue new directions on in-mission work without a formal aims-change request; and a meritorious renewal can be funded for the full five years even at reduced budget, keeping a lab running rather than lapsing it.

Applications omit the Specific Aims page entirely. NIGMS instructs applicants whose submission system will not allow this to enter: “Per the NOFO instructions, no specific aims are to be submitted.” The Research Strategy section is capped at six pages, shifting reviewer attention toward the investigator’s track record and the programme’s overall significance rather than experimental detail.

Which eligibility route applies — ESI, New Investigator, or Established Investigator?

MIRA eligibility is not a single ladder; it is three separate application pathways, each with its own notice of funding opportunity, effort requirement, and budget ceiling.

• Early Stage Investigator (ESI) MIRA (PAR-27-032): open to PIs with active ESI status in eRA Commons. NIH defines an Early Stage Investigator as a new PI within 10 years of a terminal research degree or medical residency who has not yet held R01-equivalent support (R01, R35, R37, DP1, DP2, U01, or SC1). Preliminary data are neither expected nor required.
• New Investigator (NI) MIRA: for PIs who have not competed successfully for a substantial independent NIH award but fall outside strict ESI status, applying via PAR-26-121.
• Established Investigator (EI) MIRA: for PIs already holding a qualifying single-PI R01-equivalent NIGMS award (R01, R35, R37, DP1, DP2, SC1, or an NRNM U01), applying via the same PAR-26-121 NOFO.

Per NIGMS guidance, ESI MIRA applicants must commit at least 51% of total research effort and are capped at $275,000 in annual direct costs including equipment. EI/NI recipients must commit at least 45% of total research effort — reduced from 51% effective 1 October 2024 under NOT-GM-24-054 — with EI budgets permitted to reach $750,000 in direct costs per year for five years.

How does MIRA governance differ from renewing an R01?

An R01 renewal is evaluated project by project, against the specific aims and preliminary data proposed for the next funding period. A MIRA renewal is evaluated as continued support for a laboratory’s overall NIGMS-aligned programme, and NIGMS explicitly permits funding a strong-but-not-outstanding renewal at reduced scale rather than lapsing it outright — an option that does not exist in standard R01 competing renewal.

Timing windows diverge too. A new MIRA application must be submitted no later than the end of the fiscal year following the one in which the qualifying R01-equivalent award was originally due to expire. A renewal MIRA application gets a longer window, extending to the end of the second fiscal year after the current MIRA’s original expiration — because, as NIGMS notes, the MIRA itself is the PI’s only qualifying award, unlike a PI holding two R01s who has multiple chances to trigger a new application.

Peer review differs too. NIGMS reviews MIRA applications through six standing Center for Scientific Review study sections (MRAA through MRAF), and reviewers assign a single overall impact score rather than the individual criterion scores (significance, investigator, innovation, approach, environment) used for R01 review — a deliberate design choice to keep attention on programme-level impact rather than methodological detail.

How does a MIRA interact with a P01 or other multi-project award?

A MIRA consolidates support for one investigator’s lab; a P01 Research Program Project grant does the structural opposite, coordinating several interrelated but distinct projects led by multiple named investigators around a shared scientific theme, typically supported through shared core resources.

NIGMS treats P01, P50, and RM1 awards as multi-component grants sitting outside MIRA consolidation. If a MIRA PI also leads a project on one of these awards, NIGMS adjusts the MIRA’s funding level to remove the budgetary overlap, and the PI must relinquish the multi-component funding at the end of its current competitive segment. The two mechanisms are not merged; a PI cannot fold a P01 project into a MIRA budget.

This matters for administrators tracking effort: a MIRA PI’s required 45% (EI/NI) or 51% (ESI) research effort is calculated across all their NIH awards via Other Support documentation, so a concurrent P01 role directly affects how much MIRA effort — and salary — can be charged.

Common questions about the NIH MIRA R35

What is an R35 grant from NIH?

An R35 is an NIH activity code supporting an investigator’s overall research programme rather than a discrete, aims-defined project. Multiple NIH institutes use it under different local names — NIGMS calls its version the Maximizing Investigators’ Research Award (MIRA) — each with its own eligibility rules, budget caps, and award length.

How much is the NIH MIRA R35 grant?

Budgets vary by route. NIGMS caps Established Investigator MIRA requests at $750,000 in direct costs per year for five years, while New Investigator and Early Stage Investigator MIRA budgets are generally set at or capped near $275,000 in annual direct costs, including equipment for ESIs.

What is the difference between an R35 (MIRA) and an R01 grant?

An R01 funds one defined project with specific aims and is typically renewed every three to five years on a project-by-project basis. A MIRA (R35) funds an investigator’s entire NIGMS-aligned lab programme for five years, omits specific aims, and allows in-mission research direction changes without a full competing renewal.

How long do R35 grants last?

NIGMS’s MIRA is awarded for five years and is renewable through a new competing application and peer review. Other institutes’ R35 mechanisms run longer: the National Cancer Institute’s Outstanding Investigator Award (R35) funds seven years, and NINDS’s R35 Research Program Award can extend up to eight years, per NIGMS, AAMC, and Vanderbilt University School of Medicine reporting.

What this means for research administrators

For research administration offices, MIRA changes what “renewal risk” looks like. Instead of tracking one competing renewal deadline per R01, institutions supporting a MIRA PI track a single five-year cycle, a 45–51% effort commitment reconciled against every other NIH award the PI holds, and a mandatory institutional letter confirming other NIGMS awards will be relinquished on award.

Consolidating what might otherwise have been two or three R01s into one MIRA reduces the number of competing submissions per cycle, but concentrates programmatic risk into a single review outcome, since NIGMS explicitly discourages “cramming” multiple R01-style projects into one MIRA narrative.

As NIH funding pressure pushes institutes toward programme-level mechanisms, teams supporting research administration workflows should expect other institutes to expand their own R35-family programmes, each with local eligibility and budget rules that will not mirror NIGMS’s exactly.